Warning: file_put_contents(/opt/frankenphp/design.onmedianet.com/storage/proxy/cache/685525c4c20cb16db6b08f4794e0c332.html): Failed to open stream: No space left on device in /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php on line 36

Warning: http_response_code(): Cannot set response code - headers already sent (output started at /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php:36) in /opt/frankenphp/design.onmedianet.com/app/src/Models/Response.php on line 17

Warning: Cannot modify header information - headers already sent by (output started at /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php:36) in /opt/frankenphp/design.onmedianet.com/app/src/Models/Response.php on line 20
IVX-411 - Wikipedia Jump to content

IVX-411

From Wikipedia, the free encyclopedia

IX-411
Vaccine description
TargetSARS-CoV-2
Vaccine typeVirus-like particles
Clinical data
Routes of
administration		Intramuscular

IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia.[1] It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.[2][3][4]

In 2022 results were released that the RDB antigen component of the vaccine was unstable, which resulted in reduced potency.[5]

Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Long COVID
Society
Politics
virus icon COVID-19 portal

References

[edit]
  1. ^ "ANZCTR - Registration". anzctr.org.au. Retrieved 18 August 2021.
  2. ^ "Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate - Icosavax, Inc". investors.icosavax.com. Archived from the original on 30 October 2021. Retrieved 18 August 2021.
  3. ^ "Two nanoparticle vaccines enter clinical trials". Institute for Protein Design. 2 June 2021. Retrieved 18 August 2021.
  4. ^ Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, et al. (June 2021). "Adjuvanting a subunit COVID-19 vaccine to induce protective immunity". Nature. 594 (7862): 253–258. Bibcode:2021Natur.594..253A. doi:10.1038/s41586-021-03530-2. PMID 33873199.
  5. ^ "Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones". BioSpace. 28 July 2022.
Stub icon

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=IVX-411&oldid=1246005372"